President Donald Trump has announced the resignation of FDA Commissioner Marty Makary. This follows reported backlash from both the pharmaceutical industry and the White House. Makary, appointed by Trump in February 2025, faced criticism over his handling of regulatory processes and policies that some industry insiders felt were too rigid. The White House reportedly shared these concerns, leading to tensions between Makary and the administration.
Makary, a well-known public health expert, came under fire for his approach to drug approvals and pandemic response strategies. His departure has sparked discussions about the FDA’s direction under the Trump administration, focusing on balancing industry needs with public health.
This move has left many wondering who will be appointed next and how it will affect the FDA’s future policies. The administration has yet to announce a successor.
Why This Matters to You
The FDA plays a crucial role in ensuring the safety and efficacy of medications and food products. Changes in leadership can influence how quickly new drugs hit the market and the standards for approval. For consumers, this could impact everything from drug availability to food safety standards. Keep an eye on the FDA’s next steps.
-Elijah Iraheta, Editor-in-Chief, ASC News
